Tara K. Iyer, MD

Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.

Panelists discuss how there is no change in therapeutic indication based on this particular finding, though it may serve as a beneficial side effect for patients struggling with sleep difficulties.

Panelists discuss how long-term safety data for fezolinetant and elinzanetant remain unavailable, though short-term results show very positive outcomes with significantly higher efficacy than previous treatment options.

Panelists discuss how fezolinetant and elinzanetant can cause liver-related adverse events requiring careful monitoring for drug-induced liver injury, noting that patients typically recover after discontinuation and emphasizing that primary providers are ideally positioned to manage patients with complex comorbidities.

Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).

Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).

Panelists discuss how previous therapies lacked efficacy for vasomotor symptoms, while new treatments fezolinetant and elinzanetant offer superior effectiveness, with elinzanetant specifically addressing additional symptoms beyond the primary condition.

Panelists discuss how vasomotor symptoms (VMS) can persist for years with variable manifestations, significantly disrupting both social and professional spheres, resulting in multibillion-dollar economic losses through decreased productivity and increased insurance costs.